Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response

Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response

BackgroundThe treatment of oral cancer remains challenging due to its infiltrative nature and a high tendency for tumour relapse leading to an overall poor prognosis. In the case of early recurrence, the patient’s prognosis deteriorates dramatically, with survival rate dropping to below 30%. Minimal...

Full description

Bibliographic Details
Main Authors: Manuel Olmos, Jacek Glajzer, Tjark-Ole Büntemeyer, Gesche Frohwitter, Jutta Ries, Markus Eckstein, Markus Hecht, Rainer Lutz, Marco Rainer Kesting, Manuel Weber
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
case report
immunotherapy
oral cancer
pembrolizumab
neoadjuvant
PD-1 - PD-L1 axis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.720951/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.720951/full

Similar Items